Coronavirus Information for the UC San Diego Community

Our leaders are working closely with federal and state officials to ensure your ongoing safety at the university. Stay up to date with the latest developments. Learn more.

Apratoxin A shows novel pancreas-targeting activity through the binding of Sec 61

TitleApratoxin A shows novel pancreas-targeting activity through the binding of Sec 61
Publication TypeJournal Article
Year of Publication2016
AuthorsHuang K.C, Chen Z.H, Jiang Y.M, Akare S., Kolber-Simonds D., Condon K., Agoulnik S., TenDyke K, Shen Y.C, Wu K.M, Mathieu S., Choi H.W, Zhu X.J, Shimizu H., Kotake Y., Gerwick WH, Uenaka T., Woodall-Jappe M., Nomoto K.
JournalMolecular Cancer Therapeutics
Date Published2016/06
Type of ArticleArticle
ISBN Number1535-7163
Accession NumberWOS:000377427600006
Keywordsanticancer agents; collection; cotranslational translocation; cyclodepsipeptide; endoplasmic-reticulum; inhibition; lyngbya-bouillonii; oxazoline analog; potent; protein; Translocation

Apratoxin A is a natural product with potent antiproliferative activity against many human cancer cell lines. However, we and other investigators observed that it has a narrow therapeutic window in vivo. Previous mechanistic studies have suggested its involvement in the secretory pathway as well as the process of chaperone-mediated autophagy. Still the link between the biologic activities of apratoxin A and its in vivo toxicity has remained largely unknown. A better understanding of this relationship is critically important for any further development of apratoxin A as an anticancer drug. Here, we describe a detailed pathologic analysis that revealed a specific pancreas-targeting activity of apratoxin A, such that severe pancreatic atrophy was observed in apratoxin A-treated animals. Follow-up tissue distribution studies further uncovered a unique drug distribution profile for apratoxin A, showing high drug exposure in pancreas and salivary gland. It has been shown previously that apratoxin A inhibits the protein secretory pathway by preventing cotranslational translocation. However, the molecule targeted by apratoxin A in this pathway has not been well defined. By using a H-3-labeled apratoxin A probe and specific Sec 61 alpha/beta antibodies, we identified that the Sec 61 complex is the molecular target of apratoxin A. We conclude that apratoxin A in vivo toxicity is likely caused by pancreas atrophy due to high apratoxin A exposure. (C)2016 AACR.

Short TitleMol. Cancer Ther.
Student Publication: